Finkelstein, Eric Andrew Malkin, Jesse D Baid, Drishti Alqunaibet, Ada Mahdi, Khaled Al-Thani, Mohammed Bin Hamad Abdulla Bin Belaila, Buthaina Al Nawakhtha, Ebrahim Alqahtani, Saleh El-Saharty, Sameh
...
Published in
Journal of medical economics
To estimate the current burden of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in the six countries in the Gulf Cooperation Council: Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. We used data from pre-existing datasets and the literature. We identified seven major noncommuni...
Cai, Beilei Zhou, Zheng-Yi Xue, Weiguang Hazra, Nisha C Singh, Mukesh Mishra, Dinesh Brixner, Diana Oderda, Gary Biskupiak, Joseph
Published in
Journal of medical economics
To estimate the budget impact of adding capmatinib, the first FDA approved MET inhibitor, to a US commercial or Medicare health plan for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have a mutation that leads to MET exon 14 (METex14) skipping. Target population size was estimated using published epidemiology data. Clini...
Hu, Tianyan Weiss, Thomas Bencina, Goran Owusu-Edusei, Kwame Petigara, Tanaz
Published in
Journal of medical economics
Although the incidence of invasive pneumococcal disease (IPD) and acute otitis media (AOM) in young children has decreased since the introduction of pneumococcal conjugate vaccines (PCVs), the subsequent emergence of non-vaccine Streptococcus pneumoniae serotypes and the persistence of certain vaccine serotypes both contribute to substantial residu...
Hu, Yannan Charaan, Majed van Oostrum, Ilse Heeg, Bart Bell, Timothy
Published in
Journal of medical economics
The clinical efficacy and safety of DAURISMO (glasdegib) combined with low-dose cytarabine (LDAC) were demonstrated in the BRIGHT AML 1003 study among newly diagnosed acute myeloid leukemia patients who are not eligible to receive intensive chemotherapy. This study aims to evaluate its cost-effectiveness versus LDAC alone and azacitidine from a Can...
Hosogaya, Naoki Takazono, Takahiro Yokomasu, Akira Hiroi, Shinzo Ikeoka, Hidetoshi Iwasaki, Kosuke Takeshima, Tomomi Mukae, Hiroshi
Published in
Journal of medical economics
Estimating the monetary value of the convenience of using influenza antivirals approved in Japan from a patient perspective using a conjoint analysis. An online survey (August 2020) was performed on individuals aged 20-64 years living in Japan who had taken oral or inhalant antivirals for influenza treatment in the 2018/19 or 2019/20 seasons. Effic...
Brown, C M Richards, K M Vohra, Y Kanu, C Stevens, L Sasane, R Balu, S McAneny, B
Published in
Journal of medical economics
System-level efforts have been deployed to improve oncology care and access while reducing utilization and costs. Understanding the nature of access to care from the perspective of patients themselves is an unmet need. This study examined access to care in a population of women with breast cancer and its relationship to overall patient satisfaction...
Allocati, Eleonora Godman, Brian
Published in
Journal of medical economics
Glick, Brad Guerin, Annie Ayyagari, Rajeev Lin, Tina Jacobson, Abby Joseph, George Kircik, Leon
Published in
Journal of medical economics
Narayan, Omendra Bentley, Anthony Mowbray, Katie Hermansson, Monika Pivonka, Dominic Kemadjou, Eric Ngonga Belsey, Jonathan
Published in
Journal of medical economics
Respiratory syncytial virus (RSV) is a common cause of respiratory infection in infants and severe infection can result in hospitalization. The passive immunization, palivizumab, is used as prophylaxis against RSV, however, use in the UK is restricted to populations at high risk of hospitalization. This study assesses the cost-effectiveness (CE) of...
Martignani, Cristian Massaro, Giulia Diemberger, Igor Ziacchi, Matteo Angeletti, Andrea Galiè, Nazzareno Biffi, Mauro
Published in
Journal of medical economics
